New hope for hair loss: drug shows promise in scarring alopecia trial
NCT ID NCT06240351
First seen Feb 01, 2026 · Last updated May 11, 2026 · Updated 14 times
Summary
This study tests the drug baricitinib in 15 women with frontal fibrosing alopecia, a condition that causes scarring hair loss and eyebrow loss. The goal is to see if it safely reduces disease activity and improves symptoms like itching and redness. Participants take the drug and are monitored for changes in scalp inflammation and hair loss progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.